<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The young-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:mp ids='MP_0002055'>diabetes</z:mp> seen in HNF1A-MODY is often misdiagnosed as Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, unlike HNF1A-MODY, is associated with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and a characteristic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We aimed to compare the <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles in HNF1A-MODY, Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and control subjects and to determine if <z:chebi fb="23" ids="18059">lipids</z:chebi> can be used to aid the differential diagnosis of <z:mp ids='MP_0002055'>diabetes</z:mp> sub-type </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: 1) 14 subjects in each group (HNF1A-MODY, Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and controls) were matched for gender and BMI </plain></SENT>
<SENT sid="4" pm="."><plain>Fasting <z:chebi fb="23" ids="18059">lipid</z:chebi> profiles and <z:chebi fb="17" ids="39025">HDL</z:chebi> <z:chebi fb="23" ids="18059">lipid</z:chebi> constituents were compared in the 3 groups </plain></SENT>
<SENT sid="5" pm="."><plain>2) <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> was assessed in a further 267 patients with HNF1A-MODY and 297 patients with a diagnosis of Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> to determine its discriminative value </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: 1) In HNF1A-MODY subjects, plasma-<z:chebi fb="4" ids="17855">triglycerides</z:chebi> were lower (1.36 vs. 1.93 mmol/l, p = 0.07) and plasma-<z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> was higher than in subjects with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (1.47 vs. 1.15 mmol/l, p = 0.0008), but was similar to controls </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, in the isolated <z:chebi fb="17" ids="39025">HDL</z:chebi>; <z:chebi fb="17" ids="39025">HDL</z:chebi>-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> and <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> content were higher in HNF1A-MODY, than in Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (1.59 vs. 1.33 mmol/L, p = 0.04 and 1.10 vs. 0.83 mmol/L, p = 0.019, respectively), but were similar to controls (1.59 vs. 1.45 mmol/L, p = 0.35 and 1.10 vs. 1.21 mmol/L, p = 0.19, respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>2) A plasma-<z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> &gt; 1.12 mmol/L was 75% sensitive and 64% specific (ROC AUC = 0.76) at discriminating HNF1A-MODY from Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The plasma-<z:chebi fb="23" ids="18059">lipid</z:chebi> profiles of HNF1A-MODY and the <z:chebi fb="23" ids="18059">lipid</z:chebi> constituents of <z:chebi fb="17" ids="39025">HDL</z:chebi> are similar to non-diabetic controls </plain></SENT>
<SENT sid="10" pm="."><plain>However, <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> was higher in HNF1A-MODY than in Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and could be used as a biomarker to aid in the identification of patients with HNF1A-MODY </plain></SENT>
</text></document>